Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates sustained liothyronine delivery via microneedle patches in hypothyroid rats, suggesting a viable alternative to oral thyroid hormone replacement.
Hypothyroidism is conventionally treated with thyroid hormone replacement via synthetic hormones, namely levothyroxine (LT 4 ), and in possible combination with liothyronine (LT 3 ), both administered orally. The supratherapeutic peaks and subtherapeutic troughs of LT 3 concentration after oral delivery may limit efficacy, as this pharmacokinetic profile does not mimic the relatively constant T 3 levels found in normal physiology. Microneedle patches (MNPs) provide a simple-to-use delivery method that can be formulated to achieve controlled drug release for extended periods of time. Here, we developed a MNP for LT 3 delivery into the skin as a first assessment of this approach. After examining a number of MNP formulations, we developed MNPs containing a range of different LT 3 doses in a poly(vinylpyrrolidone)-based formulation. The MNs effectively punctured the skin and achieved average LT 3 delivery efficiencies of 41–71%. LT 3 MNP administration to hypothyroid rats at three doses (10 µg, 100 µg, 1000 µg) produced elevated serum T 3 levels that persisted for 18–24 h, exhibiting a nonlinear dependence on LT 3 dose. This study established the feasibility of administering LT 3 by MNP that could be translated to enable improved therapy for patients with hypothyroidism.
No takes yet. Share an insight, caveat, or question.
Gomaa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: